3-hydroxybutyric acid has been researched along with Non-alcoholic Fatty Liver Disease in 9 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Costabile, G | 1 |
| Della Pepa, G | 1 |
| Salamone, D | 1 |
| Luongo, D | 1 |
| Naviglio, D | 1 |
| Brancato, V | 1 |
| Cavaliere, C | 1 |
| Salvatore, M | 1 |
| Cipriano, P | 1 |
| Vitale, M | 1 |
| Corrado, A | 1 |
| Rivellese, AA | 1 |
| Annuzzi, G | 1 |
| Bozzetto, L | 1 |
| Lee, S | 1 |
| Bae, J | 1 |
| Jo, DR | 1 |
| Lee, M | 1 |
| Lee, YH | 1 |
| Kang, ES | 1 |
| Cha, BS | 1 |
| Lee, BW | 1 |
| Arima, Y | 1 |
| Luukkonen, PK | 1 |
| Porthan, K | 1 |
| Ahlholm, N | 1 |
| Rosqvist, F | 1 |
| Dufour, S | 1 |
| Zhang, XM | 1 |
| Lehtimäki, TE | 1 |
| Seppänen, W | 1 |
| Orho-Melander, M | 1 |
| Hodson, L | 4 |
| Petersen, KF | 1 |
| Shulman, GI | 1 |
| Yki-Järvinen, H | 3 |
| Yang, N | 1 |
| Tanner, JA | 1 |
| Zheng, BJ | 1 |
| Watt, RM | 1 |
| He, ML | 1 |
| Lu, LY | 1 |
| Jiang, JQ | 1 |
| Shum, KT | 1 |
| Lin, YP | 1 |
| Wong, KL | 1 |
| Lin, MCM | 1 |
| Kung, HF | 1 |
| Sun, H | 1 |
| Huang, JD | 1 |
| Marinho, CC | 1 |
| Nicolato, AJPG | 1 |
| Reis, VW | 1 |
| Dos Santos, RC | 1 |
| Silva, JC | 1 |
| Faria, HP | 1 |
| Machado-Coelho, GLL | 1 |
| Sun, Y | 2 |
| Zhang, N | 1 |
| Wang, J | 2 |
| Guo, Y | 1 |
| Sun, B | 1 |
| Liu, W | 1 |
| Zhou, H | 1 |
| Yang, C | 1 |
| Wei, L | 1 |
| Ball, S | 1 |
| Dennis, JA | 1 |
| Bedanie, G | 1 |
| Nugent, K | 1 |
| Hayek, AJ | 1 |
| Scott, V | 1 |
| Yau, P | 1 |
| Zolfaghari, K | 1 |
| Goldwater, M | 1 |
| Almquist, J | 1 |
| Arroliga, AC | 1 |
| Ghamande, S | 1 |
| Wu, Q | 1 |
| Ma, W | 1 |
| Shi, R | 1 |
| Zhang, B | 1 |
| Mao, X | 1 |
| Zheng, W | 1 |
| Sbhatu, DB | 1 |
| Berhe, GG | 1 |
| Hndeya, AG | 1 |
| Abraha, HB | 1 |
| Abdu, A | 1 |
| Gebru, HA | 1 |
| Taye, MG | 1 |
| Mulugeta, A | 1 |
| Weldemichael, MY | 1 |
| Tekle, HT | 1 |
| Kidanemariam, HG | 1 |
| Surger, M | 1 |
| Angelov, A | 1 |
| Liebl, W | 1 |
| Hookey, L | 1 |
| Bertiger, G | 1 |
| Johnson, KL | 1 |
| Boules, M | 1 |
| Ando, M | 1 |
| Dahdal, DN | 1 |
| Riedl, JM | 1 |
| Posch, F | 1 |
| Prager, G | 1 |
| Eisterer, W | 1 |
| Oehler, L | 1 |
| Sliwa, T | 1 |
| Wilthoner, K | 1 |
| Petzer, A | 1 |
| Pichler, P | 1 |
| Hubmann, E | 1 |
| Winder, T | 1 |
| Burgstaller, S | 1 |
| Korger, M | 1 |
| Andel, J | 1 |
| Greil, R | 1 |
| Neumann, HJ | 1 |
| Pecherstorfer, M | 1 |
| Philipp-Abbrederis, K | 1 |
| Djanani, A | 1 |
| Gruenberger, B | 1 |
| Laengle, F | 1 |
| Wöll, E | 1 |
| Gerger, A | 1 |
| Evans, WE | 1 |
| Raynor, HA | 1 |
| Howie, W | 1 |
| Lipton, RB | 1 |
| Thomas, GJ | 1 |
| Wing, RR | 1 |
| Pavlovic, J | 1 |
| Farris, SG | 1 |
| Bond, DS | 1 |
| Hepprich, M | 1 |
| Antwi, K | 1 |
| Waser, B | 1 |
| Reubi, JC | 1 |
| Wild, D | 1 |
| Christ, ER | 1 |
| Braüner Christensen, J | 1 |
| Aasbrenn, M | 1 |
| Sandoval Castillo, L | 1 |
| Ekmann, A | 1 |
| Giver Jensen, T | 1 |
| Pressel, E | 1 |
| Haxholdt Lunn, T | 1 |
| Suetta, C | 1 |
| Palm, H | 1 |
| Mansour, FA | 1 |
| Al-Mazrou, A | 1 |
| Al-Mohanna, F | 1 |
| Al-Alwan, M | 1 |
| Ghebeh, H | 1 |
| Brown-Johnson, C | 1 |
| Safaeinili, N | 1 |
| Zionts, D | 1 |
| Holdsworth, LM | 1 |
| Shaw, JG | 1 |
| Asch, SM | 1 |
| Mahoney, M | 1 |
| Winget, M | 1 |
| Luo, Y | 1 |
| Shan, H | 1 |
| Gao, X | 1 |
| Qi, P | 1 |
| Li, Y | 2 |
| Li, B | 1 |
| Rong, X | 1 |
| Shen, B | 1 |
| Zhang, H | 1 |
| Lin, F | 1 |
| Tang, Z | 1 |
| Fang, Z | 1 |
| Peng, Z | 1 |
| Jimenez, JL | 1 |
| Ayer, GB | 1 |
| Klepov, VV | 1 |
| Pace, KA | 1 |
| Zur Loye, HC | 1 |
| Acquaroni, M | 1 |
| Svartz, G | 1 |
| Pérez Coll, C | 1 |
| Otludil, B | 1 |
| Ayaz, S | 1 |
| Hill, A | 1 |
| Elakkad, A | 1 |
| Kuban, J | 1 |
| Sabir, S | 1 |
| Odisio, B | 1 |
| Huang, SY | 1 |
| Mahvash, A | 1 |
| Miller, E | 1 |
| Kroll, MH | 1 |
| Overman, M | 1 |
| Tam, AL | 1 |
| Gupta, S | 1 |
| Sheth, RA | 1 |
| Deandreis, D | 1 |
| Guarneri, A | 1 |
| Ceci, F | 1 |
| Lillaz, B | 1 |
| Bartoncini, S | 1 |
| Oderda, M | 1 |
| Nicolotti, DG | 1 |
| Pilati, E | 1 |
| Passera, R | 1 |
| Zitella, A | 1 |
| Bellò, M | 1 |
| Parise, R | 1 |
| Carlevato, R | 1 |
| Ricardi, U | 1 |
| Gontero, P | 1 |
| Coyne, GO' | 1 |
| Wang, L | 2 |
| Zlott, J | 1 |
| Juwara, L | 1 |
| Covey, JM | 1 |
| Beumer, JH | 1 |
| Cristea, MC | 1 |
| Newman, EM | 1 |
| Koehler, S | 1 |
| Nieva, JJ | 1 |
| Garcia, AA | 1 |
| Gandara, DR | 1 |
| Miller, B | 1 |
| Khin, S | 1 |
| Miller, SB | 1 |
| Steinberg, SM | 1 |
| Rubinstein, L | 1 |
| Parchment, RE | 1 |
| Kinders, RJ | 1 |
| Piekarz, RL | 1 |
| Kummar, S | 1 |
| Chen, AP | 1 |
| Doroshow, JH | 1 |
| Li, X | 2 |
| Chen, J | 2 |
| Gan, L | 1 |
| Tian, Y | 1 |
| Shi, B | 1 |
| Yang, Y | 1 |
| Li, G | 1 |
| Wu, D | 1 |
| Wen, A | 1 |
| Wu, Y | 1 |
| Zhou, X | 1 |
| Koyappayil, A | 1 |
| Chavan, SG | 1 |
| Mohammadniaei, M | 1 |
| Go, A | 1 |
| Hwang, SY | 1 |
| Lee, MH | 1 |
| Kurokawa, Y | 1 |
| Yamashita, K | 1 |
| Kawabata, R | 1 |
| Fujita, J | 1 |
| Imamura, H | 1 |
| Takeno, A | 1 |
| Takahashi, T | 1 |
| Yamasaki, M | 1 |
| Eguchi, H | 1 |
| Doki, Y | 1 |
| Schulte, T | 1 |
| Sala, BM | 1 |
| Nilvebrant, J | 1 |
| Nygren, PÅ | 1 |
| Achour, A | 1 |
| Shernyukov, A | 1 |
| Agback, T | 1 |
| Agback, P | 1 |
| Karami, H | 1 |
| Shariatifar, N | 1 |
| Nazmara, S | 1 |
| Moazzen, M | 1 |
| Mahmoodi, B | 1 |
| Mousavi Khaneghah, A | 1 |
| Sinha, N | 1 |
| Mukhopadhyay, S | 1 |
| Sau, M | 1 |
| Qi, Y | 1 |
| Wan, M | 1 |
| Abd El-Aty, AM | 1 |
| Li, H | 2 |
| Cao, L | 1 |
| She, Y | 1 |
| Shao, Y | 1 |
| Jin, F | 1 |
| Wang, S | 1 |
| Melendez-Araújo, MS | 1 |
| Lemos, KGE | 1 |
| Arruda, SLM | 1 |
| Dutra, ES | 1 |
| de Carvalho, KMB | 1 |
| de la Plaza Llamas, R | 1 |
| Díaz Candelas, DA | 1 |
| Ramia, JM | 1 |
| Zhu, S | 1 |
| Liu, Z | 1 |
| Lu, J | 2 |
| Xiang, Z | 1 |
| Lan, J | 1 |
| Liu, J | 1 |
| Yu, M | 1 |
| Chen, Y | 2 |
| Sirajudeen, AAO | 1 |
| Annuar, MSM | 1 |
| Subramaniam, R | 1 |
| Somme, F | 1 |
| Montaz-Rosset, MS | 1 |
| Averous, G | 1 |
| Deur, J | 1 |
| Goichot, B | 1 |
| Bachellier, P | 1 |
| Addeo, P | 1 |
| Imperiale, A | 1 |
| Xu, L | 1 |
| Li, Z | 2 |
| Song, S | 1 |
| Chen, Q | 1 |
| Mo, L | 1 |
| Wang, C | 1 |
| Fan, W | 1 |
| Yan, Y | 1 |
| Tong, X | 1 |
| Yan, H | 1 |
| Singh, A | 1 |
| Chen, HC | 1 |
| Chen, YF | 1 |
| Lu, YJ | 1 |
| Wong, KT | 1 |
| Chu, CW | 1 |
| Banijamali, AR | 1 |
| Carvalho, AE | 1 |
| Wakefield, JD | 1 |
| Germano, P | 1 |
| Barden, TC | 1 |
| Tobin, JV | 1 |
| Zimmer, DP | 1 |
| Masferrer, JL | 1 |
| Profy, AT | 1 |
| Currie, MG | 1 |
| Todd Milne, G | 1 |
| Zhang, Y | 1 |
| Yang, H | 1 |
| Dang, Z | 1 |
| Zhan, S | 1 |
| Sun, C | 1 |
| Hu, G | 1 |
| Lin, Y | 1 |
| Yuan, Q | 1 |
| Karayağiz Muslu, G | 1 |
| Özdemir, M | 1 |
| Del Prete, S | 1 |
| Nocentini, A | 1 |
| Supuran, CT | 1 |
| Capasso, C | 1 |
| Chagas, ATA | 1 |
| Ludwig, S | 1 |
| Pimentel, JDSM | 1 |
| de Abreu, NL | 1 |
| Nunez-Rodriguez, DL | 1 |
| Leal, HG | 1 |
| Kalapothakis, E | 1 |
| Zhang, J | 1 |
| Lin, L | 1 |
| Dodig, D | 1 |
| Kovačić, S | 1 |
| Matana Kaštelan, Z | 1 |
| Žuža, I | 1 |
| Benić, F | 1 |
| Slaven, J | 1 |
| Miletić, D | 1 |
| Rumboldt, Z | 1 |
| Fernandez-Botran, R | 1 |
| Wellmann, IA | 1 |
| Une, C | 1 |
| Méndez-Chacón, E | 1 |
| Hernández de Rodas, E | 1 |
| Bhandari, B | 1 |
| Villagrán de Tercero, CI | 1 |
| Nguyen, HTT | 1 |
| Romano, F | 1 |
| Wampfler, R | 1 |
| Mühlethaler, K | 1 |
| Tannich, E | 1 |
| Oberli, A | 1 |
| Yang, J | 1 |
| Xiang, T | 1 |
| Dai, L | 1 |
| Zhao, X | 1 |
| Ma, L | 1 |
| Zuo, D | 1 |
| Wei, B | 1 |
| Sui, Y | 1 |
| Xu, F | 1 |
| Zheng, H | 1 |
| Qiu, C | 1 |
| Jin, H | 1 |
| Kerwin, J | 1 |
| Khan, I | 1 |
| Rajasekhar, B | 1 |
| Venkateshwaran, U | 1 |
| Durairaj, N | 1 |
| Divyapriya, G | 1 |
| Nambi, IM | 1 |
| Joseph, A | 1 |
| Aliste, M | 1 |
| Garrido, I | 1 |
| Flores, P | 1 |
| Hellín, P | 1 |
| Vela, N | 1 |
| Navarro, S | 1 |
| Fenoll, J | 1 |
| Männistö, VT | 1 |
| Simonen, M | 1 |
| Hyysalo, J | 1 |
| Soininen, P | 1 |
| Kangas, AJ | 1 |
| Kaminska, D | 1 |
| Matte, AK | 1 |
| Venesmaa, S | 1 |
| Käkelä, P | 1 |
| Kärjä, V | 1 |
| Arola, J | 2 |
| Gylling, H | 1 |
| Cederberg, H | 1 |
| Kuusisto, J | 1 |
| Laakso, M | 1 |
| Ala-Korpela, M | 1 |
| Pihlajamäki, J | 1 |
| Pramfalk, C | 1 |
| Pavlides, M | 1 |
| Banerjee, R | 1 |
| McNeil, CA | 1 |
| Neubauer, S | 1 |
| Karpe, F | 1 |
| Bhatia, L | 1 |
| Scorletti, E | 1 |
| Smith, DE | 1 |
| Jackson, NC | 1 |
| Shojaee-Moradie, F | 1 |
| Umpleby, M | 1 |
| Calder, PC | 1 |
| Byrne, CD | 1 |
| Westerbacka, J | 1 |
| Kotronen, A | 1 |
| Fielding, BA | 1 |
| Wahren, J | 1 |
| Perttilä, J | 1 |
| Seppänen-Laakso, T | 1 |
| Suortti, T | 1 |
| Hultcrantz, R | 1 |
| Castillo, S | 1 |
| Olkkonen, VM | 1 |
| Frayn, KN | 1 |
| Orešič, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Medium-term Effects of a Portfolio Diet on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients[NCT03380416] | 49 participants (Actual) | Interventional | 2017-04-04 | Completed | |||
| The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease[NCT00760513] | Phase 4 | 103 participants (Actual) | Interventional | 2009-11-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Liver Fibrosis Score is an algorithmically derived score of liver fibrosis comprising measurements of tissue matrix metalloproteinase-1 (TIMP-1), hyaluronic acid (HA) and the amino terminal end of procollagen III (PIIINP) (see Guha et al. in Reference section). The Score represents a number on a numerical scale from 0 to 20. High values of the score (measured in arbitrary units) indicate high probability of advanced liver fibrosis, low scores indicate low probability of advanced liver fibrosis. Change in Liver Fibrosis Score was used to test the intervention. Change in liver fibrosis score represented the change in measurement as calculated as the arithmetic difference between the end value minus the baseline value of the Liver Fibrosis Score. The change in Liver Fibrosis Score can therefore be negative (representing an improvement in liver fibrosis between baseline and end of study) or be positive, (representing a worsening a liver fibrosis between baseline and end of study. (NCT00760513)
Timeframe: Baseline and 18 months
| Intervention | score on a scale (Mean) |
|---|---|
| Omega 3 Fatty Acid (Fish Oil) | 0.3 |
| Dummy Pill | 0.2 |
The NAFLD fibrosis score represented a validated algorithmically-derived measure of liver fibrosis as reported in Angulo et al (see reference section). The Score is derived from anthropometric and biochemical measurements in subjects. The NAFLD fibrosis score represents an arbitrary number with no units from -5.0 to +5.0. High positive NAFLD fibrosis scores indicate a high probability of advanced liver fibrosis. Negative scores represent a low probability of advanced liver fibrosis. The change in NAFLD fibrosis score (measured in arbitrary units) was used to test the effect of the intervention and represented the arithmetic difference in the end minus baseline measurements of this score. Thus, a negative change in the Score in the Table represented an improvement in liver fibrosis score between baseline and the end of the study. A positive change in the Score in the Table represented a worsening in liver fibrosis score between baseline and end of the study. (NCT00760513)
Timeframe: Baseline and 18 months
| Intervention | score on a scale (Mean) |
|---|---|
| Omega 3 Fatty Acid (Fish Oil) | 0.8 |
| Dummy Pill | 0.8 |
Percentage of liver fat was measured using magnetic resonance spectroscopy at baseline and end of study. High percentage values indicate a lot of liver fat (scale from 0 to 100%). Change in liver fat percentage represented the arithmetical difference between end of study liver fat percentage minus baseline measurement of liver fat percentage change in liver fat percentage was used to test whether the intervention decreased liver fat percentage. A negative change value in liver fat percentage indicates a response to therapy. A positive change value indicates no response to therapy. (NCT00760513)
Timeframe: Baseline and 18 months
| Intervention | percentage of liver fat (Mean) |
|---|---|
| Omega 3 Fatty Acid (Fish Oil) | -7.9 |
| Dummy Pill | -4.6 |
1 review available for 3-hydroxybutyric acid and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
The Impact of Ketone Body Metabolism on Mitochondrial Function and Cardiovascular Diseases.
Topics: 3-Hydroxybutyric Acid; Acetone; Cardiovascular Diseases; Humans; Ketone Bodies; Mitochondria; Non-al | 2023 |
4 trials available for 3-hydroxybutyric acid and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Reduction of De Novo Lipogenesis Mediates Beneficial Effects of Isoenergetic Diets on Fatty Liver: Mechanistic Insights from the MEDEA Randomized Clinical Trial.
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus, Type 2; Diet; Humans; Lipogenesis; Non-alcoholic Fatty Liv | 2022 |
Topics: 3-Hydroxybutyric Acid; Acetazolamide; Acrylates; Administration, Intravenous; Adolescent; Adult; Aer | 2007 |
Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.
Topics: 3-Hydroxybutyric Acid; Adult; Biomarkers; Cohort Studies; Dietary Supplements; Docosahexaenoic Acids | 2017 |
Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease.
Topics: 3-Hydroxybutyric Acid; Cannabinoid Receptor Modulators; Catheterization; Deuterium; Endocannabinoids | 2010 |
4 other studies available for 3-hydroxybutyric acid and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Impaired ketogenesis is associated with metabolic-associated fatty liver disease in subjects with type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; CD36 Antigens; Diabetes Mellitus, Type 2; Humans; Non-alcohol | 2023 |
The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans.
Topics: 3-Hydroxybutyric Acid; Genetic Predisposition to Disease; Humans; Lipogenesis; Liver; Mitochondria; | 2023 |
Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans.
Topics: 3-Hydroxybutyric Acid; Acetate-CoA Ligase; Acetyl-CoA C-Acetyltransferase; Adult; Aged; Biomarkers; | 2015 |
Sex-Specific Differences in Hepatic Fat Oxidation and Synthesis May Explain the Higher Propensity for NAFLD in Men.
Topics: 3-Hydroxybutyric Acid; Adult; Aged; Carbon Dioxide; Dietary Fats; Fasting; Fatty Acids; Female; Huma | 2015 |